Komori
Pharma Foods International (2929) · InitiativeAdvanced

Expansion of DRcula Series Sales

First written in FY2023-Q1. 2 of 5 entries say "Advanced", first in FY2023-Q2. Latest entry: FY2024.

5entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2023-Q1AdvancedFY2023-Q2RestatedFY2024-Q1 – FY2024-Q22022: 12023: 220232024: 22024
Same theme, other companies
Developing the Supplement Direct-to-Consumer Business into a Core PillarA theme 3 companies write about · 0 as a headwind · 4 as a tailwind

0 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2024AdvancedAnnual report

    「The medicated whitening gel DRcula (キュラ) and ラクトロン錠, among others, contributed to earnings as core products.」

    DRcula has progressed from being described in terms of expanding orders and subscription customers to contributing to earnings as a core product alongside ラクトロン錠.
  2. FY2024-Q2RestatedAnnual report

    「Orders for the medicated whitening gel DRcula (キュラ) remained strong, contributing to an increase in the number of subscription customers.」

    The company reconfirms that strong orders for DRcula have continued and contributed to an increase in the number of subscription customers.
  3. FY2024-Q1RestatedAnnual report

    「Orders for the medicated whitening gel DRcula (キュラ) increased, particularly through web advertising, contributing to an increase in the number of subscription customers.」

    The company continues to state that DRcula has contributed to increased orders and growth in the number of subscription customers through web advertising.
  4. FY2023-Q2AdvancedAnnual report

    「The DRcula (キュラ) series, a new product launched during the current fiscal year, generated increased orders as a result of more active web advertising, and sales of the medicated whitening gel reached ¥849 million. In terms of customer acquisition, the number of subscription customers for the medicated whitening gel and mouthwash combined reached 67,617.」

    The DRcula series generated increased orders as a result of more active web advertising, with sales of the medicated whitening gel reaching ¥849 million and the number of subscription customers for related products reaching 67,617.
  5. FY2023-Q1First statedAnnual report

    「The DRcula® (Cula) series, a new product for the current fiscal year, saw orders increase following intensified online advertising. The combined number of subscription customers for the whitening gel and mouthwash reached 62,596. In response to strong demand, the company is currently accepting advance orders and shipping products in sequence.」

    For the DRcula series, the company has disclosed for the first time the expansion of orders through web advertising, 62,596 subscription customers, and a sales process involving advance sales followed by phased shipments.
Moved together

"GABA Expansion in Japan and Overseas" moved the same way as this thread, in the same document, in 2 of its 5 moves.

222222★123456
  1. ★This thread
  2. 1GABA Expansion in Japan and Overseas2×
  3. 2Development of antibody therapeutics using proprietary chicken antibody technology2×
  4. 3Aggressive business investment aimed at sustained long-term growth and increased corporate value2×
  5. 4Functional Materials business: lower revenue and profit2×
  6. 5Raising Working Capital through Borrowings2×
  7. 6Research and Development Expenditure2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Pharma Foods International yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Expansion of DRcula Series Sales | Pharma Foods International Co.,Ltd. (2929) | Komori